Cisplatin and paclitaxel are standard chemotherapy for metastatic ovarian cancer, but with limited efficacy. Cancer stem/progenitor cells (or tumor-initiating cells, TICs) are hypothesized to be chemoresistant, and the existence of TICs in ovarian cancer has been previously demonstrated. However, the key signals and molecular events regulating the formation and expansion of ovarian tumorinitiating cells (OTICs) remain elusive. Here, we show that c-Kit is not just a marker of OTICs, but also a critical mediator of the phenotype that can be a viable target for the treatment of ovarian cancer. In contrast to non-OICs, c-Kit was overexpressed in OTICs. Moreover, the use of small interfering RNA to inhibit c-Kit expression markedly attenuated the number and size of OTIC subpopulations, inhibited the expression of stem cell markers and decreased the tumorigenic capabilities of OTICs. Imatinib (Gleevec), a clinical drug that blocks c-Kit kinase activity, also demonstrated its inhibition potency on OTICs. In addition, cisplatin/ paclitaxel, which killed non-OTICs, with c-Kit knockdown or imatinib revealed that this was critically required for intervening ovarian cancer progression and recurrence in vitro and in xenograft tumors in vivo. Similar results were obtained with OTICs derived from ovarian carcinoma patients. Studies into the mechanisms suggest an important role for the activation of Wnt/b-catenin and ATPbinding cassette G2 downstream of c-Kit. The tumor-promoting microenvironment, such as hypoxia, could promote OTICs via upregulation of c-Kit expression. These results unravel an integral role for c-Kit in ovarian neoplastic processes and shed light on its mechanisms of action.
INTRODUCTION
Ovarian cancer represents one of the most challenging cancers to treat. Cancers of the ovary have the highest mortality of all the gynecologic cancers, as 70-75% of women with ovarian cancer are diagnosed in an advanced stage (stage III or IV). 1 The majority of patients are highly responsive to current systemic chemotherapies, including cisplatin and paclitaxel, which are widely used to treat ovarian cancer; however, therapeutic resistance develops in nearly all patients. Salvage therapies are largely ineffective, with a poor 5-year survival rate of o25%. 2 Thus, understanding the underlying molecular mechanisms as a first step in developing approaches to preventing or reversing this resistance is an important area of therapeutic research.
One promising approach in this field is to study cancer stem/ progenitor cell (or tumor-initiating cell, TIC) survival signaling pathways. The presence of TICs has been demonstrated in various cancers. TICs have been shown by sorting for Hoechst negative side population cells or stem cell markers, and can also be enriched by spheroids in suspension cultures, which most closely mimic malignant ascites in advanced stages of ovarian carcinoma. [3] [4] [5] [6] [7] In contrast to other tumor cells, TICs are drug resistant and display the ability to self-renew and differentiate. As such, it is envisioned that the relapse after remission is likely due to the inability of standard chemotherapies to kill TICs despite the effective elimination of bulk tumor. 8 Nonetheless, the key signals and molecular events regulating the formation and expansion of TICs remain elusive.
Ovarian cancer is characterized by the overexpression of several cytokines, growth factors and tyrosine kinase receptors. 9 Of particular interest is c-Kit, which has been shown to function as a stem cell factor (SCF) receptor, and is now being recognized for its aberrant activation in cancer. [10] [11] [12] While activating c-Kit mutations have not been found in ovarian cancer, abnormal c-Kit expression has been described and increased c-Kit expression has been correlated with poorer patient outcomes. [10] [11] [12] However, targeted therapy alone in clinical settings in general has not proven to be successful. 13, 14 In this study, we provide evidence for a role of c-Kit in ovarian tumor-initiating cells (OTICs) phenotypes, tumorigenic properties and chemoresistance-each contributing to treatment failure of ovarian cancer. Furthermore, we show for the first time that a novel Wnt/b-catenin and ATP-binding cassette G2 (ABCG2) pathway in this process, and the tumor-predisposing microenvironment, such as hypoxia, can promote OTICs through upregulation of c-Kit expression.
RESULTS

OTICs show increased c-Kit and SCF expression
Using a functional enrichment strategy based on the selfrenewing characteristics of TICs to grow as spheres or sphereforming cells in nonadherent, stem-cell-selective condition that has previously been used to successfully obtain highly enriched TICs from cancerous ovarian tissues, 3, 5 we identified OTICs in SKOV-3 and HEYA8 cell lines. Both cell lines exhibited sphereforming efficiency (B1%) and the typical size (B100 mM diameter) was consistent with TICs from primary ovarian cancers (Figure 1a) . 5 The OTICs were also positive for the stem cell markers Bmi-1, Nanog and Oct4 in comparison with their nonsphere-forming (non-OTICs) counterparts (Figure 1b) . Under differentiating conditions by withdrawal of growth factors and addition of 10% FBS (fetal bovine serum), these OTIC spheroids adhered and formed symmetric colonies (Figure 1c) . Moreover, the differentiated cells had reduced expression of each stem cell marker (Bmi-1, Nanog and Oct4) vs spheroid cells (Figure 1d ), providing further evidence of their undifferentiated phenotype. We also detected a significant increase in the CA125 tumor antigen, which is an important indicator of the clinical progression of ovarian carcinomas, in OTIC lysates. In contrast, non-OTICs expressed little or no CA125 (Figure 1e ). To test the in vivo tumorigenic potential, we injected exponentially smaller numbers of OTICs compared with non-OTICs s.c. into flanks of nude mice. We showed that as few as 100 OTICs were able to recapitulate the original tumor in athymic nude mice and could be serially passaged (Figure 1f , left; Table 1 ). In contrast, 10 000 non-OTICs injected had no evidence of disease (Figure 1f , left; Table 1 ). All these tumors were similar to those in the histopathology of human ovarian cancer (Figure 1f, right) . Therefore, our results show that these OTICs isolated from tumor spheres have all the features of TICs.
In further defining these OTICs, with a focus on constitutive cytokine/growth factor signaling, we showed that a high level of c-Kit was unique to OTICs, whereas c-Kit was undetectable in non-OTICs (Figure 2a reaction (RT-PCR) revealed that OTICs produced higher expression of SCF (Figure 2a) . The c-Kit and SCF expression were lost during differentiation (Figure 2a ). High levels of SCF were also observed in the cell lysates (data not shown) and conditioned media of OTICs (Figure 2b ), suggesting that the high malignancy of these cells may be associated with an efficient SCF-c-Kit signaling axis. c-Kit overexpression enhances self-renewal and expansion of OTICs To start unraveling the importance of c-Kit in OTICs, we utilized a short hairpin RNA (shRNA) specifically engineered towards c-Kit. RT-PCR showed the effectiveness of this shRNA to deplete c-Kit expression (Figure 2c, inset) . Here, we provide evidence that c-Kit shRNA abrogated tumor sphere formation and caused a marked decrease in OTIC growth (Figure 2c ). In contrast, nonspecific shRNA had no effect (Figure 2c ). To clarify that the growth inhibition observed was attributed to apoptosis, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was performed. Under these conditions, TUNEL-positive cells were observed in the presence of c-Kit inhibition ( Supplementary  Figure 1a) , our data being consistent with previous observations. 15 The induction of apoptosis was further verified by western blot analysis on active (cleaved) caspase 3 (Supplementary Figure 1b) . To further confirm the role of c-Kit and to explore if therapeutic agents that block SCF-c-Kit activation are able to eliminate OTIC expansion, we tested imatinib (also known as STI571 or Gleevec), a clinically used c-Kit, BCR/ABL, and platelet-derived growth factor receptor (PDGF-R) inhibitor and an FDA-approved anti-cancer drug. Concurrent with the above results, imatinib significantly inhibited both sphere formation and growth of OTICs (Po0.005; Figure 2d ). At no time did we observe an effect of c-Kit shRNA or imatinib on non-OTIC cell proliferation (Figure 2e ), indicating distinct differences between OTICs and non-OTICs and that the SCF/c-Kit axis is functionally important in OTIC cell proliferation and survival. The effect of imatinib could be entirely reversed by the concomitant overexpression of an imatinib-resistant c-Kit mutant (V654A), confirming the specific role of c-Kit in these processes (Figure 3 ). c-Kit inhibition reduces OTIC resistance to chemotherapeutic drugs in vitro and in vivo To investigate whether SCF-c-Kit confers chemoresistance to cells, we tested whether treatment of OTICs with a combination of cisplatin/paclitaxel, the two first-line chemotherapeutic agents currently used for treating unresectable ovarian cancer, and c-Kit inhibitors would inhibit OTIC selection. In OTICs, we found great resistance to cisplatin and paclitaxel at clinically relevant doses of 50 mM and 100 nM, 16 and only a partial reduction in sphere formation was observed (Figure 4 ). On the other hand, targeting c-Kit expression or its activity by means of shRNA or imatinib alone dramatically reduced OTIC growth, and in combination with the same doses of cisplatin or paclitaxel resulted in an increase in cell sensitivity to drugs than that induced by either individually (Figures 4a and b) . Both sphere formation and growth in Figure 5a consistently supported the in-vitro observations, demonstrating drug-induced death by c-Kit shRNA/imatinib in OTIC-enriched sphere cultures generated from three primary ovarian cancer samples. The difference was statistically significant (Po0.05; Figure 5a ). To further validate its role in the promotion of cell growth, we used mouse xenograft ovarian tumors. c-Kit shRNA/ imatinib or combined therapy showed an effective sensitization to chemotherapy, with reducing growth of c-Kit by 72.7, 88.7 and 81.3%, and imatinib by 44.4, 60.1 and 51.7% compared with control, cisplatin and paclitaxel alone, respectively (Figure 5b) . Collectively, these data strongly support the tumorigenic role of c-Kit in ovarian cancer.
The higher drug resistance of c-Kit-positive OTICs encouraged us to assess whether c-Kit inhibition will be effective in eliminating OTICs from the bulk cell population and thus increase the treatment efficacy. Cisplatin or paclitaxel and c-Kit shRNA/imatinib were used either alone or in combination. The drug treatments were repeated six times, which mimic the clinical regimen that ovarian cancer patients receive, as set by the National Comprehensive Cancer Network Guidelines http://www.nccn.org/professionals/physician_gls/f_guidelines.asp). We found that while cisplatin or paclitaxel substantially reduced cell numbers of the non-OTICs (Figure 6a) , a small population of cells started to proliferate and were able to form tumor spheres when replated in stem-cell-selective condition (Figure 6b ). Furthermore, these chemoresistant cancer cells had all the TIC markers (e.g., Bmi-1, Nanog and Oct4) and SCF and c-Kit were also most elevated in these colonies from refractory tumor cells (Figure 6c ). By contrast, growing clones of OTICs were not found after combined treatment of cisplatin or paclitaxel and c-Kit shRNA/imatinib (Figure 6b ). These data suggest that chemoresistant ovarian cancer cells may actually be expanded from drug therapy, and a combination of cisplatin or paclitaxel and c-Kit shRNA/imatinib could be highly efficient against the regeneration of drugresistant TICs.
Hypoxia increases c-Kit expression, enhances OTIC survival and chemoresistance To investigate the physiological relevance of c-Kit expression to OTICs, we explored the potential regulation of c-Kit by hypoxia, which is a common feature in the ovarian cancer microenvironment. 17 To test whether hypoxia might regulate c-Kit expression, cells were subjected to hypoxic conditions (1% O 2 ) or hypoxia mimetics such as DFX (desferrioxamine), 18 and found that hypoxia/DFX significantly induced c-Kit expression in both nonOTICs and OTICs (Figure 7a ). Using RT-PCR, we found a strong upregulation of HIF-1a mRNA in OTICs as compared with nonOTICs, suggesting that HIF-1a may mediate c-Kit activation by hypoxia (Figure 7b ). Knocking down HIF-1a by small interfering RNA (siRNA) inhibited hypoxia-mediated c-Kit expression (Figure 7c ). In line with this, there was also a strong inhibition of tumor sphere formation and drug resistance (Figure 8a ), and this inhibition was counteracted by c-Kit overexpression (Figure 8b ). These data indicate a functional importance for hypoxia/HIF-1a in determining c-Kit expression, enhancement of OTIC population and chemoresistance. Chemoresistance and protumorigenic properties of c-Kit WK Chau et al c-Kit overexpression induces ABCG2 Next, we inquired the mechanism by which c-Kit modulates OTIC survival and its possible role in chemoresistance. The high expression of specific ABC drug transporters, which can efflux chemotherapeutic drugs, is a particularly intriguing property of TICs. 19 We observed enhanced mRNA levels of ABCG2 in OTICs as compared with non-OTICs (Figure 9a for 72 h. The efficiency of knockdown c-Kit was verified by mRNA levels using RT-PCR (inset). The number of tumor spheres generated was photographed and counted (left and middle). Bar, 50 mM. Cell viability was determined by MTT assay (right). The absorbance of wells not exposed to treatments was arbitrarily set as 1, and cell growth after treatment was expressed as the fold changes compared with the control.
(e) Similar experiments were also performed in non-OTICs. Experiments were repeated three times, and data are shown as mean±s.d. **Po0.005 vs control or NS shRNA.
To uncover the molecular mechanisms for increased ABCG2 expression, we focused on signaling events that converge on b-catenin, which has an essential role in the regulation of selfrenewal or carcinogenesis potential. 20 Since accumulation of b-catenin plays a critical role in directing cell fate, 21 we examined the levels of b-catenin in c-Kit shRNA-treated OTICs by western blot analysis. Endogenous b-catenin protein levels were efficiently and specifically reduced in the presence of c-Kit shRNA (Figure 10a ). No inhibition was observed for nonspecific shRNA (Figure 10a ). c-Kit regulates ABCG2 through b-catenin Previously, we showed that activated Akt enhances stabilization of functional b-catenin through inhibiting glycogen synthase kinase 3 beta (GSK3b)-mediated phosphorylation of b-catenin. 22 Here, we found that changes in p-Akt were concurrently correlated with the downregulation of b-catenin in c-Kit knockdown OTICs (Figure 10a ). Addition of LY294002 not only completely abolished activation of Akt, but also reduced b-catenin and ABCG2 levels ( Figure 10b ). Similar ABCG2 expression patterns were seen in bcatenin siRNA-treated SKOV-3 and HEYA8 cells, confirming the effect was b-catenin specific (Figure 10c ).
b-Catenin is known to mediate effects on target genes via its interaction with TCF/LEF transcription factors, 23 and evidence exists that correlate increased levels of b-catenin with increased levels of nuclear active b-catenin. 24 Hence, we studied the effect of c-Kit on the transcriptional activity of b-catenin-TCF. The luciferase reporters, which encode either wild-type (TOPFLASH) or mutated (FOPFLASH) binding sites for the b-catenin-TCF complex, have been widely used to characterize b-catenin-TCF-dependent gene expression. 23 In support of the observation, expression of dominant-negative TCF (DN-TCF) repressed ABCG2 expression (Figure 10d ). c-Kit shRNA, LY294002 or DN-TCF treatment significantly inhibited TOPFLASH activation (Figure 10e ). Importantly, enhanced chemoresistance in OTICs could be reversed by b-catenin siRNA with increased drug sensitivity to combined cisplatin/paclitaxel and b-catenin siRNA significantly (Figure 11a ). There was also a clear reduction of drug-induced death by DN-TCF (Figure 11a ). Conversely, the chemosensitizing effect by c-Kit shRNA could be rescued by expression of a stable mutant of b-catenin (S37A), which cannot be degraded by the proteasome complex (Figure 11b ). Together, these data indicate a role for ABCG2 in the increased chemoresistance by c-Kit expression, and the effect was mediated via phosphatidylinositol 3-kinase (PI3K)/Akt and b-catenin/TCF signaling.
DISCUSSION
One of the greatest unmet needs compromising the successful treatment of ovarian cancer is chemoresistance. The eradiation of TICs is thought to be a prerequisite for cure. However, we still have a very limited understanding of the underlying mechanisms. Here, we report that c-Kit is not just a marker of OTICs, but also a critical mediator of the phenotype and a viable treatment target. Since endothelial, stromal and immune cells secrete SCF, 25, 26 this signaling axis may also play a role in mediating interactions between TICs and the tumor microenvironment. These data have shed new light on approaches for a more efficacious treatment against difficult-to-treat chemoresistant ovarian cancer.
Our findings also provide a probable explanation as to why the use of imatinib as monotherapy in clinical trials did not achieve satisfactory results. 13, 14, 27, 28 This seems to be due to lack of the c-Kit expression by the non-TIC tumor population. Indeed, despite the controversial prognostic significance of c-Kit expression in ovarian cancer, c-Kit is highly expressed in a small subset of ovarian carcinoma cells in tumors of advanced patients. 11 Therefore, the development of a combination therapy targeting not only the TIC population, but also the non-TIC tumor cells will be necessary to improve the management of ovarian cancer. 29 Since the concentrations of imatinib used in our experiments, which are in line with previous studies from other groups, 30 are within the pharmacologically attainable levels of 0.1-3.4 mg/ml (0.17-5.68 mM) in the plasma to the commonly used dose of 25-600 mg imatinib daily, 31 our findings are also particularly relevant to pharmacological approaches. Imatinib inhibits not only c-Kit but also PDGF-R signaling. 31 PDGF-R is frequently expressed in human ovarian tumors and cancer cell lines and can be observed in OTICs (Supplementary Figure 2) . 29, 32 However, imatinib inhibits PDGF-R signaling at much higher concentrations than those used in this study. 31 The use of Similar experiments were also performed using imatinib (Ima; 2 mM). The number of tumor spheres generated was photographed (left) and counted (top right). Bar, 50 mM. Cell viability was determined by MTT assay (bottom right). The absorbance of wells not exposed to treatments was arbitrarily set as 1, and cell growth after treatment was expressed as the fold changes compared with the control. Experiments were repeated three times, and data are shown as mean±s.d. **Po0.005 vs control.
imtaintib-resistant c-Kit mutant (V654A) and c-Kit shRNA further indicates that c-Kit is the predominant target.
One important question concerning TICs is whether this population is actually expanded by drug therapy. Using a prolonged, multistep selection regimen, we showed that this could result in the expansion of a sphere-forming cancer stem cell-like population with a highly chemotherapy-resistant phenotype. Our finding is also especially intriguing in view of the fact that tumor spheres are commonly found in malignant ascites of ovarian cancer patients and a likely source of recurrent disease. 33 The observations that c-Kit is highly expressed in recurrent ovarian carcinomas and that high c-Kit expression correlates with chemoresistance further suggest that c-Kit activation may be associated with tumor aggressiveness. 11, 29, 34 Our data presented here clearly indicate that c-Kit is required for the prosurvival effects in ovarian cancer cells. It is likely that c-Kit may also regulate other processes, including cell adhesion, differentiation and migration, which are significant with respect to cancer development and treatment. 35 c-Kit can also induce the expression of key angiogenesis genes, such as vascular endothelial growth factor (Supplementary Figure 3) . Thus, the identification of c-Kit as a novel target of OTIC function is of considerable interest.
The importance of the microenvironment in tumor progression has been increasingly recognized. 36 High HIF-1a expression is associated with high-grade ovarian cancer and correlates with poor survival. 37, 38 Our present data extend these observations and suggest that HIF-1a mRNA was upregulated in the OTIC population compared with the non-OTIC population, which may provide an explanation for our observation that c-Kit is highly expressed and can be induced by hypoxia in OTICs. Using a computer-assisted search for binding motifs, we found consensus HIF-1 response elements within the c-Kit promoter (data not shown). This is the first demonstration that c-Kit is a target gene of HIF-1a activation and adding HIF-1a as a new member of c-Kit transcriptional modulator.
What mechanisms might be responsible for c-Kit-conferred chemoresistance? Our data indicate an important role for ABCG2 downstream of c-Kit. Although different mechanisms may be involved, the rapid drug elimination by drug transporters is of particular interest because it clearly supports OTIC survival as well as improves drug efficacy. This may also explain why a stem cell population is resistant to multiple chemotherapeutic agents rather than being specific to one agent. [4] [5] [6] This observation follows clinically, in which most ovarian cancer patients who develop resistance to platinum agents have resistance to multiple agents. 39 We also show that b-catenin is a novel transcriptional mediator of ABCG2 expression. In support, LEF/TCF binding sites CTTTGA/ TA/T 40 within the human ABCG2 gene promoter (accession number AH011213 41 ) can be identified. The b-catenin/TCF pathway has been implicated in the regulation of other ABC drug transporters. 42 In general, there are two ways that Wnt/b-catenin signaling can contribute to oncogenesis, specifically mutations in the genes encoding adenomatous polyposis coli (APC) or b-catenin. Both of which disrupt the degradation of b-catenin by the proteasome, resulting in increased levels of free b-catenin, which on activation interacts with TCF to initiate transcription of target genes. 23 grade and poor survival. [43] [44] [45] It is also relevant to the clinical situation that Wnt/b-catenin and ABCG2 are significantly overexpressed in recurrent lesions, suggesting that the in-vitro regulation that we showed in cell cultures might be found in situ in ovarian carcinomas. 46, 47 The PI3K/Akt represents one of the key pathways controlling cell survival, proliferation and growth. The clinical relevance of the PI3K/Akt in c-Kit-driven ovarian cancer was supported by the observation that ovarian cancer patients, who showed lower survival when expressing higher c-Kit levels, also tend to have a worse outcome when expressing higher p-Akt levels.
14 Although the mechanism of b-catenin could also be mediated through a MAPK pathway, 48 we ruled out this possibility in c-Kit effects since treatment of cells with a specific inhibitor of MEK1 (PD98059) had no effect on the TCF activity. Nor did it alter the growth of OTICs (data not shown).
Our findings clearly demonstrate that the c-Kit is a key regulator of OTIC survival and proliferation, and its inhibition potentiates TIC cell death. This novel function of c-Kit in ovarian cancer biology may provide a rationale for future clinical studies to use a combination of conventional chemotherapeutic drugs with c-Kit inhibitor for intervening cancer progression and recurrence much needed for the management of ovarian cancer.
MATERIALS AND METHODS
Cells and cell culture
Human ovarian carcinoma cell lines SKOV-3 and HEYA8 were gifts from Dr N Auersperg (University of British Columbia, Vancouver, BC, Canada) and Dr J Liu (MD Anderson Cancer Center, Houston, TX, USA), respectively. Cells were grown in medium 199:MCDB105 (1:1) supplemented with 10% FBS (Hyclone), and 100 units/ml penicillin/streptomycin at 37 1C in a humidified atmosphere containing 5% CO 2 . Isolation and culture of spheres from SKOV-3 and HEYA8 or primary human ovarian cancer samples were performed in serum-free stem-cell-selective condition as described in Zhang et al. 5 Briefly, 1-2 weeks after plating, nonadherent spherical clusters of cells could be observed and were separated from single cells by low speed centrifugation. The single cells remaining viable grew adherently after being transferred to the serum-containing medium, but they did not generate new spheres. On 8th to 10th passages, the nonadherent spherical clusters of cells appeared as distinct spheres, and sphere-forming efficiency calculated based on the numbers of initially seeded cells. Using this selection condition, we obtained spheres in a sustainable culture that could be enzymatically dissociated and reformed into spheres within 3 days under stem-cell-selective condition. To allow differentiation, dissociated sphere cells were plated on tissue culture plates under regular culture conditions in medium with 10% FBS. Primary tumor samples were obtained from ovarian cancer patients with informed consent and approval by the Tri-Service General Hospital Institutional Review Board. To generate drug tolerant subpopulations, cisplatin, paclitaxel or imatinib alone or in combination were used. The drug treatment was repeated six times, with fresh media-containing drug being replaced every 3 days under normal culture condition, and each treatment lasting for 1-2 weeks. In all, 495% of cells underwent apoptosis or senescence and eventually died, thereby selecting the most resistant clones. Viable cells remained attached on the plate at the end of drug treatment were collected for analysis.
Drugs
Imatinib was from Cayman Chemical (Ann Arbor, MI, USA) and was dissolved in DMSO to produce a 100-mM stock solution and was used at 2 mM. Cisplatin and paclitaxel were purchased from Calbiochem (San Diego, CA, USA) and were used at 50 mM and 100 nM concentration, respectively. LY294002 and PD98059 were also obtained from Calbiochem. The drugs and inhibitors were added after the formation of the spheres, and counting of sphere numbers and MTT analysis were performed after 3 days.
Reverse transcription and PCR
Total RNA was extracted with Trizol and reversed transcribed, and the cDNA was synthesized using the first-stranded cDNA synthesis kit Cell viability was determined by MTT assay (bottom right). The absorbance of wells not exposed to treatments was arbitrarily set as 1, and cell growth after treatment was expressed as the fold changes compared with the control. Experiments were repeated three times, and data are shown as mean±s.d. *Po0.05; **Po0.005 vs control or NS shRNA. 
Western blot analysis
Equal amounts of cell lysate proteins were separated on 7.5% sodium dodecyl sulfate polyacrylamide gels and transferred to nitrocellulose membrane. Membranes were blocked for 1 h at room temperature with 5% nonfat milk, and then incubated overnight at 4 1C in the primary antibody: rabbit anti-SCF (1:5000) (Abcam, Cambridge, UK), mouse anti-phospho-Akt (1:1000), rabbit 
Proliferation and chemosensitivity analysis
Rates of proliferation and sensitivity to drugs were assessed using the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay according to the manufacturer's instructions (Sigma). Briefly, 500 ml MTT solution was added to each well and the plate was incubated for 4 h at 37 1C. Medium was then aspirated from each well, and 250 ml DMSO was added. Colorimetric analysis was performed at a wavelength of 570 nm using a microplate reader (Bio-Rad).
Cell apoptosis
To assess cell apoptosis, TUNEL was performed using a commercially available In Situ Cell Death Detection kit (Roche, Indianopolis, IN, USA) to find DNA breaks according to the manufacturer's instructions. 4 0 ,6-diamidino-2-phenylindole (DAPI) was used to label the nuclei. Further characterization of apoptosis was analyzed by western blotting with a rabbit anti-caspase 3 (1:1000) (Cell Signaling).
Constructs and transfections
To express cDNA constructs, dissociated OTICs were transiently transfected with 1 mg of plasmid DNA per well in six-well plates for 24 h using Lipofectamine (Invitrogen). Cells were reseeded in stem-cell-selective medium to reform spheres before experimental analyses. Wild-type c-Kit and the imatinib-resistant c-Kit mutant V654A were gifts from Dr L Ashman (University of Newcastle, NSW, Australia). 49 The ABCG2 construct was provided by Dr D Ross (University of Maryland, Baltimore, MD, USA), 41 and b-catenin S37A was described elsewhere. 22 
RNA interference
For shRNA transduction, lentiviruses carrying c-Kit (SHGLY-NM-000222) or nonspecific shRNA (SHC002) were prepared by co-transfection of 293T cells with the constructs and lentiviral packaging mix (Sigma) using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. Conditioned media containing the infectious viral particles were collected at 48 h post-transfection and filtered through 0.4 mM filters. These particles were then used to transduce SKOV-3 and HEYA8 for 24 h, and the transfected cells were selected with 1 mg/ml puromycin. Transfection of the ABCG2 ( . Cell viability was determined by MTT assay. The absorbance of wells not exposed to treatments was arbitrarily set as 1, and cell growth after treatment was expressed as the fold changes compared with the control. Experiments were repeated three times, and data are shown as mean ± s.d. *Po0.05; **Po0.005 vs control or NS shRNA.
(Invitrogen). Transfection efficiencies were determined by co-transfection of the b-galactosidase construct. Luciferase and b-galactosidase activity were assayed according to the manufacturer's protocol using the luciferase assay kit from Promega (Madison, WI, USA). Luciferase activity in each well was normalized to the b-galactosidase activity. All experiments were assayed in triplicates, and the assay was performed in three independent experiments.
Ovarian xenograft tumor
Equal number of cells from non-OTICs and OTICs were suspended in 100 ml of PBS and injected s.c. into the right rear flank to 6-to 8-week-old-female athymic nude mice (BALB/c-nu/nu). When tumors reached a diameter of 1 cm, the mice were killed and tumors were harvested for further examination. Those animals injected with tumor cells but with no sign of tumor burden were generally terminated 24 weeks after inoculation. For pathological examination, tissue sections were fixed on formalin, embedded in paraffin blocks and H&E stained. For the in vivo treatment, 10 5 OTICs were inoculated into the nude mice s.c. When tumors were grown for B3 weeks (tumor size 50 mm 
Statistical analysis
All data were presented as mean±s.d. of at least three different experiments. One-way analysis of variance was used to evaluate statistical significance, and the Tukey test was performed to detect differences (GraphPad Software, San Diego, CA, USA). P-values of o0.05 are considered statistically significant.
